17.99
-0.61(-3.28%)
Currency In USD
| Previous Close | 18.6 |
| Open | 18.44 |
| Day High | 18.6 |
| Day Low | 17.71 |
| 52-Week High | 72 |
| 52-Week Low | 6.76 |
| Volume | 390,130 |
| Average Volume | 818,733 |
| Market Cap | 157.69M |
| PE | 0.06 |
| EPS | 279.15 |
| Moving Average 50 Days | 18.3 |
| Moving Average 200 Days | 26.88 |
| Change | -0.61 |
If you invested $1000 in Tonix Pharmaceuticals Holding Corp. (TNXP) 10 years ago, it would be worth $0 as of December 18, 2025 at a share price of $17.99. Whereas If you bought $1000 worth of Tonix Pharmaceuticals Holding Corp. (TNXP) shares 5 years ago, it would be worth $0.05 as of December 18, 2025 at a share price of $17.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
GlobeNewswire Inc.
Dec 16, 2025 12:00 PM GMT
Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain Compelling safety and pharmacokinetic profiles in animals support IND-enabling studies CHATHAM, N.J., Dec. 16, 2025 (GLO
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
GlobeNewswire Inc.
Dec 09, 2025 12:00 PM GMT
Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industryCHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”),
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
GlobeNewswire Inc.
Nov 24, 2025 12:00 PM GMT
Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026 More than 21 million US adults experience a major depressive episode each year CHATHAM, N.J., Nov. 24, 2025 (GLOBE N